Validation of novel predictors for early detection of cancer therapeutics-related cardiac dysfunction.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2025-02-16 DOI:10.1080/14796678.2025.2466379

Marwan S Mahmoud, Moustafa Morsy, Mohamed Abdel Ghany, Naglaa K Idriss, Hatem Abdelrahman Helmy, Yehia T Kishk

{"title":"Validation of novel predictors for early detection of cancer therapeutics-related cardiac dysfunction.","authors":"Marwan S Mahmoud, Moustafa Morsy, Mohamed Abdel Ghany, Naglaa K Idriss, Hatem Abdelrahman Helmy, Yehia T Kishk","doi":"10.1080/14796678.2025.2466379","DOIUrl":null,"url":null,"abstract":"Background: Early identification of cardiotoxicity of chemotherapy is crucial. Gene expression is considered a promising tool.Aim: To validate the new speckle tracking values, high-sensitive (Hs) troponin and expression of TNNI3K and RyR2 genes for early detection of cardiotoxicity.Methods: Fifty patients with cancer breast on Anthracycline chemotherapy were subjected to speckle tracking echocardiography and Hs troponin measurement. Relative expression of TNNI3K and RyR2 genes were determined by RT-PCR.Results: Fifty female patients with age (43.89 ± 6.4) were included. Fourteen patients (28%) developed cardiotoxicity, diagnosed by decrease GLS > 15%. Compared to GLS, Hs-Troponin has sensitivity 73%, specificity 100%, PPV 78.5% and NPV 100%. Cutoff point of GLS > 10% had sensitivity 95%, specificity 78%, PPV 81% and NPV 84%. Using a cutoff of 24% change in TNNI3K Expression; sensitivity 100%, specificity 74%, PPV 79.5% and NPV 100%. Using a cutoff of 25% in RYR-2 expression; sensitivity 67% and specificity 59% with less PPV and NPV (62% and 64%). Adding GLS change >10% to Hs troponin and TNNI3K expression resulted in highest sensitivity (100%) and specificity (95.5%) with 96% PPV and 100% NPV.Conclusion: Cutoff point of GLS > 10%, Hs-Troponin and TNNI3K gene expression are reliable test for early detection of cardiotoxicity.Trial registration number (irb): 042024100222.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-7"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2466379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Early identification of cardiotoxicity of chemotherapy is crucial. Gene expression is considered a promising tool.

Aim: To validate the new speckle tracking values, high-sensitive (Hs) troponin and expression of TNNI3K and RyR2 genes for early detection of cardiotoxicity.

Methods: Fifty patients with cancer breast on Anthracycline chemotherapy were subjected to speckle tracking echocardiography and Hs troponin measurement. Relative expression of TNNI3K and RyR2 genes were determined by RT-PCR.

Results: Fifty female patients with age (43.89 ± 6.4) were included. Fourteen patients (28%) developed cardiotoxicity, diagnosed by decrease GLS > 15%. Compared to GLS, Hs-Troponin has sensitivity 73%, specificity 100%, PPV 78.5% and NPV 100%. Cutoff point of GLS > 10% had sensitivity 95%, specificity 78%, PPV 81% and NPV 84%. Using a cutoff of 24% change in TNNI3K Expression; sensitivity 100%, specificity 74%, PPV 79.5% and NPV 100%. Using a cutoff of 25% in RYR-2 expression; sensitivity 67% and specificity 59% with less PPV and NPV (62% and 64%). Adding GLS change >10% to Hs troponin and TNNI3K expression resulted in highest sensitivity (100%) and specificity (95.5%) with 96% PPV and 100% NPV.

Conclusion: Cutoff point of GLS > 10%, Hs-Troponin and TNNI3K gene expression are reliable test for early detection of cardiotoxicity.

Trial registration number (irb): 042024100222.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.